Weekend reads: A CRISPR retraction; questions about football concussion data; an ethicist who has led to more than 20 retractions

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured a university’s findings that dozens of papers by a famous … Continue reading Weekend reads: A CRISPR retraction; questions about football concussion data; an ethicist who has led to more than 20 retractions

Journal flags paper on painkiller for misused trial registry record

A pain journal has expressed concern over a 2018 paper by a group of researchers in China after a reader alerted the publication to problems with the article, including previously-reported data and a bogus trial registry record.  The article, “Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative … Continue reading Journal flags paper on painkiller for misused trial registry record

“I decline to respond” but “take this history to undermine”

There are various ways to respond to criticism of one’s work. There is the “well, that’s not pleasant news, but thank you, I’ll correct that straightaway” approach. There’s the “I guess we’ll correct this but hope no one notices” approach. There’s the “I’m suing you” approach — often followed by “never mind.” And then there’s … Continue reading “I decline to respond” but “take this history to undermine”

“Do we have the will to do anything about it?” James Heathers reflects on the Eysenck case

We have a tension about resolving inaccuracies in scientific documents when they’re past a certain age. Specifically, what should we do with old papers that are shown to be not just wrong, which is a fate that will befall most of them, but seriously misleading, fatally flawed, or overwhelmingly likely to be fabricated, i.e. when they … Continue reading “Do we have the will to do anything about it?” James Heathers reflects on the Eysenck case

University finds dozens of papers by late — and controversial — psychologist Hans Eysenck “unsafe”

More than two dozen papers by a controversial psychologist who died in 1997 are “unsafe,” according to a recent report by his former employer obtained by Retraction Watch. The research has been subject to question for decades, because the findings — including some that “bibliotherapy” could dramatically reduce the risk of dying from cancer — … Continue reading University finds dozens of papers by late — and controversial — psychologist Hans Eysenck “unsafe”

Weekend reads: The need for more honesty in science; a fight between authors of a GM mosquito paper; faked academic CVs

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured a case of doing the right thing in autism research; … Continue reading Weekend reads: The need for more honesty in science; a fight between authors of a GM mosquito paper; faked academic CVs

Drip, drip: Former Harvard stem cell researcher up to 18 retractions

Piero Anversa, a former star researcher at Harvard Medical School who left the institution under a cloud, is up to 18 retractions. But that’s barely half of the 31 papers by Anversa’s group that Harvard has requested journals pull over concerns about the integrity of the findings.  The two articles, published in the Proceedings of … Continue reading Drip, drip: Former Harvard stem cell researcher up to 18 retractions

Health care group withdraws rheumatoid arthritis drug report

An influential group that studies the economic burden of medical care has temporarily removed from its website a draft report about the cost-effectiveness of drugs to treat rheumatoid arthritis amid questions about the modeling researchers used in their analysis.   The group initially did little to explain the move, despite having issued a press release for … Continue reading Health care group withdraws rheumatoid arthritis drug report

Weekend reads: Jailed for publishing a paper; pushing back on vaping research; “sugar daddy science”

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured lots of news involving Nature, including the retraction of a … Continue reading Weekend reads: Jailed for publishing a paper; pushing back on vaping research; “sugar daddy science”

PLOS ONE retracts perfume study when data don’t pass the sniff test

A pair of perfume researchers in England have lost a 2019 paper on what makes a scent appealing because, ahem, something about the data didn’t smell quite right.  The article was titled “Social success of perfumes,” and it appeared in July in PLOS ONE. There was a press release and a university writeup about the … Continue reading PLOS ONE retracts perfume study when data don’t pass the sniff test